XML 71 R64.htm IDEA: XBRL DOCUMENT v3.25.1
Segment Information - Summary of significant segment expenses and segment net loss (Details) - USD ($)
$ in Thousands
 3 Months Ended 12 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Dec. 31, 2024
Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Abstract]      
Canvuparatide direct program expense $ 8,337 $ 3,982  
MBX 1416 direct program expense 1,806 2,636  
Preclinical and other research and development direct expense 6,985 842  
Research and development overhead expense 5,277 3,589  
Other segment items [1] 1,475 1,288  
Net loss $ 23,880 $ 12,337 $ 32,600
[1]

(1) Other segment items are primarily comprised of general and administrative expenses and interest and other income.